A carregar...
Long-Term Follow-Up of Mesothelioma Patients Treated with Dendritic Cell Therapy in Three Phase I/II Trials
Background: Malignant pleural mesothelioma (MPM) is a fatal neoplasm with, if untreated, poor survival of approximately nine months from diagnosis. Until recently, phase II–III immunotherapy trials did not show any significant benefit. The lack of immunotherapy efficacy can be explained by the fact...
Na minha lista:
| Publicado no: | Vaccines (Basel) |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8158710/ https://ncbi.nlm.nih.gov/pubmed/34069348 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/vaccines9050525 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|